Phase 1 N=49 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Squamous Cell Carcinoma of the Head and Neck · Melanoma · Non Small Cell Lung Cancer
Primary: Safety Profile of SL-279252 — 1; 1; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=64 Thorough QT/QTc of Pritelivir in Healthy Subjects
Healthy Subjects
Primary: Effects of Pritelivir on the QTcF Interval (QTc Using Fridericia Correction Method) in Comparison With Placebo in Male and Female Subjects. — 402.66; 405.23; 401.94…
Phase 1 N=21 Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
Gastroenteritis
Primary: Safety of HIL-214 Compared to Placebo - AEs Leading to Trial Withdrawal — 0; 0 Percentage of Participants
Phase 1 N=17 Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
End-Stage Renal Disease (ESRD) · End-Stage Kidney Disease (ESKD) · Kidney Failure, Chronic
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 10; 4 Participants
Phase 1 N=23 RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
Covid19
Primary: Grade 2 and Higher Adverse Events 4 Weeks After Administration. — 0; 0; 0; 0 Participants
Phase 1 N=40 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
Migraine
Primary: Number of Participants With Treatment-Emergent Adverse Events — 7; 8; 6; 8 Participants
Phase 1 N=16 A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
Healthy
Primary: Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine — 39100; 37400 hour*nanogram per milliliter (h*ng/mL)
Phase 1 N=69 An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
Neoplasms
Primary: Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 1; 1; 1 Participants
Phase 1 N=22 First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE)…
Phase 1 N=48 Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19
SARS-CoV-2
Primary: The Number of Participants With Serious Adverse Events Following Administration of ADM03820 to the Final Visit — 1; 1; 0; 0 Participants
Phase 1 N=12 Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Erectile Dysfunction Following Radical Prostatectomy · Erectile Dysfunction · Prostate Cancer
Primary: Cmax — NA ng/mL
Phase 1 N=20 A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib — 51700; 45500 hour nanogram per milliliter…
Phase 1 N=70 Study of UB-312 in Healthy Participants and Parkinson's Disease Patients
Parkinson's Disease · Parkinsonism
Primary: Frequency of Adverse Events — 22; 31; 25; 31 TEAEs
Phase 1 N=127 A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 36.0; 39.1; 8.3; 35.3 Percentage of participants
Phase 1 N=18 The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets
Influenza
Primary: HAI Titers